Nuvectra (NASDAQ:NVTR) Trading 22.2% Higher
Nuvectra Corp (NASDAQ:NVTR) shares traded up 22.2% on Tuesday . The company traded as high as $0.25 and last traded at $0.22, 5,631,100 shares changed hands during mid-day trading. An increase of 876% from the average session volume of 576,804 shares. The stock had previously closed at $0.18.
A number of equities analysts have weighed in on the stock. Raymond James lowered shares of Nuvectra from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 13th. Zacks Investment Research lowered shares of Nuvectra from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. JMP Securities dropped their price target on shares of Nuvectra to $10.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. They noted that the move was a valuation call. Piper Jaffray Companies dropped their price target on shares of Nuvectra from $18.00 to $4.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Finally, ValuEngine lowered shares of Nuvectra from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Nuvectra has a consensus rating of “Hold” and an average price target of $8.75.
The firm has a market capitalization of $3.14 million, a P/E ratio of -0.04 and a beta of 0.69. The stock’s 50-day simple moving average is $1.22 and its two-hundred day simple moving average is $2.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.86 and a quick ratio of 4.42.
Nuvectra Company Profile (NASDAQ:NVTR)
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Featured Article: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.